Efficacy and survival of photodynamic treatment for tracheal adenoid cystic carcinoma: a two-center retrospective analysis

光动力疗法治疗气管腺样囊性癌的疗效和生存率:一项双中心回顾性分析

阅读:2

Abstract

BACKGROUND: Tracheal adenoid cystic carcinoma (TACC) is a rare malignant tumor with limited treatment options for unresectable cases. Although case reports have indicated the value of photodynamic therapy (PDT), its efficacy, survival outcomes, and prognostic factors remain poorly characterized. This two-center retrospective study aimed to evaluate the long-term outcomes of patients with TACC treated with PDT and to identify predictors of treatment response. METHODS: A retrospective analysis was conducted on 39 patients with TACC who received continuous PDT treatment in two hospitals from August 2011 to September 2023. All patients were intravenously injected with hematoporphyrin derivative (HpD) at a dose of 2 mg/kg and treated 48 hours later. The therapeutic effect was evaluated according the 2019 efficacy evaluation standard for PDT for respiratory tumors. The primary endpoints were overall survival (OS) and progression-free survival (PFS), while the secondary endpoints included objective response rate (ORR) and safety. The prognostic factors were analyzed via a Cox regression model. RESULTS: The study included 39 patients, with a mean age of 47.51±14 years (range, 19-79 years). The most recent efficacy evaluation of 39 patients, conducted 1 month after PDT treatment, showed complete response (CR) in 5 patients, partial response (PR) in 25 patients, and progressive disease (PD) in 9 patients. Both OS and PFS were significantly longer in the PR group than in the PD group (OS: P=0.008; PFS: P=0.005). The 5-, 10-, and 15-year survival rates for patients were 73.2%, 64.1%, and 42.7%, respectively. Only 7 patients experienced complications. Univariate Cox regression analysis indicated that the age and treatment interval were significant risk factors for the emergence of TACC (P=0.03). CONCLUSIONS: We found that PDT for patients with TACC achieved satisfactory clinical efficacy and safety, resulting in longer survival and fewer complications. Moreover, treatment interval and age were risk factors for the development of TACC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。